US biotechnology company Inovio Pharmaceuticals Inc's (Nasdaq:INO) planned mid-to-late-stage trial of its experimental COVID-19 candidate was put on partial clinical hold by the US Food and Drug Administration, which sought additional information, Reuters news agency reported on Monday.
According to Inovio Pharmaceuticals, it was working to address the agency's queries by October 2020, including on the vaccine delivery device, after which the US agency would have 30 days to decide whether the trial should proceed.
The company said the pause was not due to any side effects in its early-stage study of the vaccine, which is continuing.
In June 2020 Inovio Pharmaceuticals had reported encouraging results from an early-stage human trial of its experimental COVID-19 vaccine candidate, INO-4800.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma